Aspiriant LLC Has $660,000 Stock Position in Thermo Fisher Scientific Inc. $TMO

Aspiriant LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the second quarter, HoldingsChannel.com reports. The firm owned 1,628 shares of the medical research company’s stock after selling 63 shares during the quarter. Aspiriant LLC’s holdings in Thermo Fisher Scientific were worth $660,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Root Financial Partners LLC increased its holdings in Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 24 shares during the last quarter. Rossmore Private Capital boosted its holdings in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock worth $2,315,000 after buying an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its position in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after buying an additional 24 shares during the period. Finally, Somerville Kurt F increased its stake in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock valued at $651,000 after acquiring an additional 25 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMO. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Robert W. Baird lifted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, Barclays boosted their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $589.10.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $539.05 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $203.55 billion, a price-to-earnings ratio of 31.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock’s 50-day moving average is $495.74 and its 200-day moving average is $449.13.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 EPS. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.